Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Location: France, Ile-de-France
Employees: 11-50
Total raised: $97.39M
Founded date: 2016
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.02.2024 | - | $5.3M | - |
| 25.03.2019 | - | $50.92M | - |
| 04.05.2017 | Series A | $41.18M | - |
Mentions in press and media 15
| Date | Title | Description |
| 01.02.2024 | France-based Vivet Therapeutics raises EUR 4.9 million in funding | Paris, France-based clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders, Vivet Therapeutics, raised EUR 4.9 million in funding. The company announced the investment on Janua... |
| 01.02.2024 | Vivet Therapeutics Receives EUR 4.9M Financing | Vivet Therapeutics, a Paris, France-based clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders, received EUR 4.9M in funding. The French Government as part of the France Heal... |
| 12.01.2022 | VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease | Paris, France and New York, NY, August 12, 2021 – Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designati... |
| 13.04.2021 | Vivet Therapeutics, participada por Ysios Capital y Columbus Venture, cierra una opción exclusiva de licencia con Mirum Pharmaceuticals | 13/04/2021 Nota de prensa MIRUM PHARMACEUTICALS Y VIVET THERAPEUTICS FIRMAN UN ACUERDO EXCLUSIVO DE OPCIÓN Y LICENCIA A ESCALA MUNDIAL PARA LOS PROGRAMAS DE TERAPIA GÉNICA DE VIVET DIRIGIDOS A LA COLESTASIS INTRAHEPÁTICA FAMILIAR PROGRESI... |
| 13.04.2021 | Vivet Therapeutics, participated by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals | 13/04/2021 Press release MIRUM PHARMACEUTICALS AND VIVET THERAPEUTICS ENTER INTO EXCLUSIVE WORLDWIDE OPTION AND LICENSE AGREEMENT FOR VIVET’S GENE THERAPY PROGRAMS TARGETING PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS. – Mirum expands ... |
| 25.03.2019 | Vivet Therapeutics Receives €45M Investment from Pfizer | Vivet Therapeutics, a Paris, France-based gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, received a 15% equity investment from Pfizer Inc. (NYSE: PFE). Pfizer also... |
| 20.03.2019 | Pfizer adquiere una participación del 15% en Vivet Therapeutics, participada por Ysios Capital | 20/03/2019 Nota de prensa PFIZER ADQUIERE UNA PARTICIPACIÓN DEL 15% EN VIVET THERAPEUTICS, PARTICIPADA POR YSIOS CAPITAL. Vivet Therapeutics (“Vivet”), compañía biotecnológica participada por la entidad de capital riesgo (venture capital... |
| 04.05.2017 | Term Sheet — Thursday, May 4 | ET CETERA New money: Heap, an analytics software company, has raised $27 million in Series B funding led by NEA and Menlo Ventures with participation from Initialized Capital and Pear VC. Heap CEO and co-founder Matin Movassate created the ... |
| 04.05.2017 | Vivet Therapeutics Raises €37.5M in Series A Financing | Vivet Therapeutics, a Paris, France-based biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, raised €37.5m in a Series A financing round. The round was led by Novartis Venture Fund and Columbus Ven... |
| - | Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics | Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease Pfizer acquires 15% ownership stake in Vivet Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”), a privately he... |
Show more